DK3412674T3 - Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser - Google Patents
Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser Download PDFInfo
- Publication number
- DK3412674T3 DK3412674T3 DK17747007.7T DK17747007T DK3412674T3 DK 3412674 T3 DK3412674 T3 DK 3412674T3 DK 17747007 T DK17747007 T DK 17747007T DK 3412674 T3 DK3412674 T3 DK 3412674T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- methods
- trifluoroacetate salt
- tlr7 agonist
- crystalline crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081899.3A CN107043377A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| PCT/CN2017/072894 WO2017133687A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3412674T3 true DK3412674T3 (da) | 2020-11-09 |
Family
ID=59500539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17747007.7T DK3412674T3 (da) | 2016-02-05 | 2017-02-04 | Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10683296B2 (da) |
| EP (1) | EP3412674B1 (da) |
| JP (1) | JP6877450B2 (da) |
| KR (1) | KR102393281B1 (da) |
| CN (2) | CN107043377A (da) |
| AR (1) | AR107550A1 (da) |
| AU (1) | AU2017214135B2 (da) |
| BR (1) | BR112018015878A2 (da) |
| CA (1) | CA3013521C (da) |
| CL (1) | CL2018002101A1 (da) |
| DK (1) | DK3412674T3 (da) |
| EA (1) | EA037048B1 (da) |
| ES (1) | ES2834304T3 (da) |
| HK (1) | HK1259182A1 (da) |
| HU (1) | HUE052210T2 (da) |
| IL (1) | IL260981B (da) |
| MX (1) | MX2018009503A (da) |
| NZ (1) | NZ745023A (da) |
| PH (1) | PH12018501641A1 (da) |
| SG (1) | SG11201806688QA (da) |
| TW (1) | TWI778952B (da) |
| UA (1) | UA121276C2 (da) |
| WO (1) | WO2017133687A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN112105620A (zh) * | 2018-05-25 | 2020-12-18 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| CN115666637A (zh) | 2020-03-02 | 2023-01-31 | 蛋白科技先锋 | 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法 |
| EP4194006A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| KR101687841B1 (ko) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
| US9139590B2 (en) * | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) * | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| CN104837840B (zh) * | 2012-10-10 | 2017-08-08 | 爱尔兰詹森科学公司 | 用于治疗病毒感染及其他疾病的吡咯并[3，2‑d]嘧啶衍生物 |
| CN104780924B (zh) * | 2012-11-20 | 2016-09-14 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
| CN106232603B (zh) * | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| EA032487B1 (ru) * | 2014-05-01 | 2019-06-28 | Новартис Аг | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| US9962388B2 (en) | 2014-08-15 | 2018-05-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-02-05 CN CN201610081899.3A patent/CN107043377A/zh active Pending
-
2017
- 2017-02-03 TW TW106103697A patent/TWI778952B/zh active
- 2017-02-04 BR BR112018015878-0A patent/BR112018015878A2/pt active Search and Examination
- 2017-02-04 HU HUE17747007A patent/HUE052210T2/hu unknown
- 2017-02-04 ES ES17747007T patent/ES2834304T3/es active Active
- 2017-02-04 US US16/075,303 patent/US10683296B2/en active Active
- 2017-02-04 UA UAA201809128A patent/UA121276C2/uk unknown
- 2017-02-04 CA CA3013521A patent/CA3013521C/en active Active
- 2017-02-04 CN CN201780009751.1A patent/CN108602833B/zh active Active
- 2017-02-04 JP JP2018540797A patent/JP6877450B2/ja active Active
- 2017-02-04 SG SG11201806688QA patent/SG11201806688QA/en unknown
- 2017-02-04 EA EA201891772A patent/EA037048B1/ru not_active IP Right Cessation
- 2017-02-04 NZ NZ745023A patent/NZ745023A/en unknown
- 2017-02-04 KR KR1020187024629A patent/KR102393281B1/ko active IP Right Grant
- 2017-02-04 WO PCT/CN2017/072894 patent/WO2017133687A1/zh active Application Filing
- 2017-02-04 MX MX2018009503A patent/MX2018009503A/es active IP Right Grant
- 2017-02-04 EP EP17747007.7A patent/EP3412674B1/en active Active
- 2017-02-04 AU AU2017214135A patent/AU2017214135B2/en active Active
- 2017-02-04 DK DK17747007.7T patent/DK3412674T3/da active
- 2017-02-06 AR ARP170100299A patent/AR107550A1/es unknown
-
2018
- 2018-08-02 PH PH12018501641A patent/PH12018501641A1/en unknown
- 2018-08-03 CL CL2018002101A patent/CL2018002101A1/es unknown
- 2018-08-05 IL IL260981A patent/IL260981B/en unknown
-
2019
- 2019-01-24 HK HK19101232.5A patent/HK1259182A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3412674T3 (da) | Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser | |
| DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| EP3436455A4 (en) | NOVEL SALTS AND CRYSTALS | |
| DK3184519T3 (da) | Syreadditionssalt af trk-hæmmende forbindelse | |
| HK1259170A1 (zh) | 一種tlr7激動劑的晶型a、其製備方法和用途 | |
| DK3043785T3 (da) | Anvendelse af r-ketamin og salt deraf som lægemidler | |
| DK3412671T3 (da) | TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former | |
| DK3484978T3 (da) | Klare saltopløsninger med høj densitet | |
| DK3798222T3 (da) | Krystallinsk form af den frie base af lorlatinib | |
| DK3067355T3 (da) | Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat | |
| DK3215493T3 (da) | Syntese af copanlisib og dihydrochloridsalt deraf | |
| DK3560925T3 (da) | Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3347006T3 (da) | Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf | |
| DK3636640T3 (da) | Krystal af heterocyclidenacetamidderivat | |
| DK3359725T3 (da) | Indretning og fremgangsmåde til reorientering/orientering og justering af klæde | |
| PL3327012T3 (pl) | Krystaliczne postacie bilastyny i sposoby ich wytwarzania | |
| DK3248967T3 (da) | Krystallinsk form af et benzimidazolderivat og en fremstillingsfremgangsmåde herfor | |
| DK3248981T3 (da) | C14-hydroxyl-forestrede aminosyrederivater af triptolid, og fremstillingsfremgangsmåde og anvendelse deraf | |
| DK3725786T3 (da) | KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE | |
| DK3286190T3 (da) | Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao) | |
| DK3323485T3 (da) | Krystalliseringssøjle og krystalliseringsfremgangsmåde | |
| DK3226888T3 (da) | Administration af en selektiv inhibitor af il-6-trans-signalering | |
| DK3371147T3 (da) | Innovativ fremstilling og krystallisering af iosimenol |